Microsurgical Treatment of Drug-Resistant Epilepsy: Amygdalohippocampectomy

Amygdalohippocampectomy is a specialized surgical treatment used in patients with drug-resistant epilepsy, i.e., those who have not responded to anticonvulsant medications. This microsurgical procedure focuses on the removal of the brain areas responsible for seizures, specifically the amygdala and hippocampus, which are key structures involved in many cases of temporal epilepsy.

 

What is Amygdalohippocampectomy?

 

Amygdalohippocampectomy is a surgery that involves the partial removal of two areas of the brain: the amygdala and the hippocampus, located in the temporal lobe. These structures are essential for emotional control and memory, but in patients with temporal epilepsy, they are often disrupted and are the source of seizures.

The goal of surgery is to eliminate or significantly reduce epileptic activity in these areas of the brain, which can lead to a substantial improvement in the patient’s quality of life by reducing or eliminating seizures.

 

Surgery Procedure

 

Amygdalohippocampectomy is performed under general anesthesia. The first step is the performance of preoperative studies, such as electroencephalograms (EEG), magnetic resonance imaging (MRI) and possibly other functional tests to precisely locate the area of the brain that is causing the seizures.

During surgery, a small incision is made in the scalp to access the temporal part of the brain. Using microsurgical techniques, the neurosurgeon removes the amygdala and a portion of the hippocampus. The surgery can be performed using a conventional (open) approach or, in some cases, using more minimally invasive techniques, such as endoscopic surgery or laser-assisted surgery, depending on the location and size of the affected area.

The procedure usually lasts between 3 and 6 hours, depending on the complexity of the case.

 

Benefits of the Procedure

 

– Seizure Reduction: Amygdalohippocampectomy has been shown to be very effective in reducing or even eliminating seizures in many patients with pharmacoresistant epilepsy.

– Improved Quality of Life: By reducing the frequency and severity of seizures, many patients experience a significant improvement in their quality of life, with greater freedom to carry out daily activities.

– Alternative to Medications: Surgery can reduce or eliminate the need for anticonvulsant medications, which often have side effects and are not always effective in patients with pharmacoresistant epilepsy.

Recovery

 

Recovery after amygdalohippocampectomy varies according to the patient and the type of surgery performed. In general, the hospital stay is a few days to monitor postoperative status and manage any possible complications. Pain or discomfort may be experienced at the incision site, which is managed with analgesics.

After surgery, rest and limitation of physical activities is recommended for a certain period of time. Most patients can resume normal activities within a few weeks, although long-term follow-up is required to assess the evolution of seizures and cognitive function.

 

Conclusion

 

Amygdalohippocampectomy is an effective surgical treatment for patients with drug-resistant epilepsy, providing a long-term solution for seizure control, improving the patient’s quality of life. At Advanced Neurosurgery Barcelona, we are committed to providing personalized and detailed attention at every step of the process, from initial evaluation to post-operative follow-up. If you have any further questions or concerns about this treatment, please do not hesitate to contact us. We are here to help you find an effective solution for your well-being.

Pathologies:

Technology used:

 

For your convenience, you can also request an appointment online.